Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000495671 | SCV000578414 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2017-06-29 | reviewed by expert panel | curation | Synonymous substitution variant, with low bioinformatic likelihood to result in a splicing aberration (Splicing prior probability 0.02; http://priors.hci.utah.edu/PRIORS/). |
Ambry Genetics | RCV000163184 | SCV000213705 | likely benign | Hereditary cancer-predisposing syndrome | 2016-02-09 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Color Diagnostics, |
RCV000163184 | SCV000688419 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001442093 | SCV001645035 | likely benign | Hereditary breast ovarian cancer syndrome | 2022-05-20 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002498807 | SCV002808595 | likely benign | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2022-04-18 | criteria provided, single submitter | clinical testing |